SCHEMBL1094378

SCHEMBL1094378

Cc1nnc(-c2ccc(F)cc2NS(=O)(=O)c2ccc(C(C)(C)C)cc2)n1C(C)C

nearest known ligand 0.44

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HSD17B2 P37059 7/20 0.42
▸ PGAM1 P18669 1/20 0.42
▸ KDM1A O60341 1/20 0.42
▸ CCR9 P51686 5/20 0.42
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ UQCRB P14927 1/20 0.40
▸ MOGAT2 Q3SYC2 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1094383 0.88 HSD17B2 (0.55) HSD17B2CCR9
SCHEMBL1095643 0.86 BRPF1 (0.45) HSD17B2PGAM1CCR9KDM4EALDH1A1
SCHEMBL1094762 0.84 CCR9 (0.44) HSD17B2PGAM1KDM1ACCR9KDM4E
SCHEMBL1094088 0.82 CCR9 (0.60) HSD17B2CCR9
SCHEMBL1094417 0.77 HSD17B2 (0.42) HSD17B2PGAM1KDM1ACCR9KDM4E
SCHEMBL1035106 0.76 HSD17B2 (0.47) HSD17B2CCR9
SCHEMBL1094660 0.74 HSD17B2 (0.46) HSD17B2CCR9KDM4EALDH1A1LMNA
SCHEMBL1094116 0.73 CCR9 (0.56) HSD17B2CCR9
SCHEMBL1094021 0.72 CCR9 (0.44) HSD17B2CCR9
SCHEMBL1094242 0.72 HSD17B2 (0.43) HSD17B2CCR9KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481579-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2013-07-09 — — US claimed
US-20120165303-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2012-06-28 — — US claimed
US-8153818-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2012-04-10 — — US claimed
EP-2046762-B1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX INC (US) 2011-02-16 — — EP claimed
US-20100190762-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2010-07-29 — — US claimed
EP-2046762-A2 TRIAZOLYL PHENYL BENZENESULFONAMIDES ChemoCentryx Inc (US) 2009-04-15 — — EP claimed
US-20080039465-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. 2008-02-14 — — US claimed
WO-2008010934-A2 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2008-01-24 — — WO claimed
US-8481579-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2013-07-09 — — US disclosed
US-8481579-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2013-07-09 — — US disclosed
US-8481579-B2 Triazolyl phenyl benzenesulfonamides CHEMOCENTRYX, INC. (US) 2013-07-09 — — US disclosed
US-20120165303-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2012-06-28 — — US disclosed
US-20120165303-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2012-06-28 — — US disclosed
US-20120165303-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2012-06-28 — — US disclosed
EP-2046762-A2 TRIAZOLYL PHENYL BENZENESULFONAMIDES ChemoCentryx Inc (US) 2009-04-15 — — EP disclosed
US-20080039465-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. 2008-02-14 — — US disclosed
US-20080039465-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. 2008-02-14 — — US disclosed
US-20080039465-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. 2008-02-14 — — US disclosed
WO-2008010934-A2 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2008-01-24 — — WO disclosed
WO-2008010934-A2 TRIAZOLYL PHENYL BENZENESULFONAMIDES CHEMOCENTRYX, INC. (US) 2008-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165303-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CCR9, CCR2, CCR1 HSD17B2 3849/4885PGAM1 3774/4885KDM1A 4262/4885
US-20100190762-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CCR9, CCR2, CCR1 HSD17B2 3849/4885PGAM1 3774/4885KDM1A 4262/4885
US-20080039465-A1 TRIAZOLYL PHENYL BENZENESULFONAMIDES CCR9, CCR2, CCR1 HSD17B2 3849/4885PGAM1 3774/4885KDM1A 4262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback